Navidea Biopharmaceuticals Price Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.23 on Friday. Navidea Biopharmaceuticals has a 12-month low of $0.21 and a 12-month high of $1.55. The business’s 50 day moving average is $0.27 and its 200-day moving average is $0.58. The stock has a market cap of $7.48 million, a P/E ratio of -0.58 and a beta of 1.36.
Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) last posted its quarterly earnings results on Monday, August 15th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $0.06 million during the quarter.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
- Get a free copy of the StockNews.com research report on Navidea Biopharmaceuticals (NAVB)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey’s a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn’t Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.